New hope for HER2+ breast cancer: could pyrotinib cut recurrence?
NCT ID NCT04254263
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 34 times
Summary
This study tests whether adding the drug pyrotinib to standard trastuzumab therapy can further reduce the chance of breast cancer returning in women with HER2-positive breast cancer who still have cancer cells after initial chemotherapy and anti-HER2 treatment. About 316 women with early-stage but locally advanced breast cancer will be randomly assigned to receive either standard care or standard care plus pyrotinib. The goal is to see if the combination improves how long women stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
RECRUITINGShanghai, Shanghai Municipality, 200127, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.